Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 702 results for "warner chilcott"

S-3ASR - Warner Chilcott Ltd (0001620602) (Filer)

Document Format Files Seq Description Document Type Size 1 FORM S-3 ASR d874808ds3asr.htm S-3ASR 543111 2 EX-4.6 d874808dex46.htm EX-4.6 427097 3 EX-5.1 d874808dex51.htm EX-5.1 31139 4 EX-5.2 d874808dex52.htm EX-5.2 39661 5 EX-5.3 d874808dex53.htm ... SEC, 1 week ago

WARNER CHILCOTT LTD - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for the historical information contained herein, the following discussion contains forward-looking statements that are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from ...
 Pharmacy Choice1 week ago ACTAVIS PLC - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS  Pharmacy Choice1 week ago

Warner Chilcott Co, LLC v. Teva Pharms. USA, Inc

Winter 2014 Case Name: . , Nos. 2014-1439, 2014-1441, 2014-1444, 2014-1445, 2014-1446, 2014 U.S. App. LEXIS 21946 (Fed. Cir. Nov. 18, 2014) (Circuit Judges Lourie, Reyna and Taranto presiding; Opinion by Lourie, J.) (appeal from D. Del., Stark, ...
 JD Supra1 week ago

69.5% Return Seen to Date on SmarTrend Warner Chilcott Call (WCRX)

(SmarTrend(R) Spotlight via COMTEX News Network) -- SmarTrend identified an Uptrend for Warner Chilcott (NASDAQ:WCRX) on January 17th, 2013 at $13.53. In approximately 23 months, Warner Chilcott has returned 69.54% as of today's recent price of ...
 PredictWallStreet2 months ago
Mail.com

Actavis : Non-GAAP Net Revenue Increases 44% to $4 Billion in Fourth Quarter 2014; Non-GAAP EPS Increases 23% to $3.91; Increases 2015 Standalone...

Actavis Non-GAAP Net Revenue Increases 44% to $4 Billion in Fourth Quarter 2014; Non-GAAP EPS Increases 23% to $3.91 ; Increases 2015 Standalone Forecast By a News Reporter-Staff News Editor at Biotech Week -- Actavis plc (NYSE: ACT) reported ...
 4 Traders1 day ago Actavis Tops Views, Announces Name Change To Allergan  Investor's Business Daily1 week ago Actavis plans name change to Allergan Drugmaker Actavis is planning to change its name as it draws closer to finishing another big deal, the $66 billion purchase of Botox maker Allergan that it announced last fall  Mail.com6 days ago Actavis Changing Name to Allergan  Wall Street Journal UK1 week ago
[x]  

Vit D Blog: Op-ed Urges Supplement Skepticism

Vitamin D trials with almost a hundred thousand people are ongoing, with results starting to come in at the end of 2017. And until those results help fill the gaps in our knowledge of vitamin D , doctors should err on the side of caution and avoid ...
 MedPage Today2 days ago

With Inversion Ban, Foreign Suitors Can Outbid Homegrown

The Treasury Department's crackdown on tax inversions last year has slowed but not stopped the movement of U.S. headquarters abroad as American businesses try to reduce tax bills and foreign firms seek to grow. Indeed, with U.S. companies now ...
 Yahoo! Finance3 days ago Tax System Gives Edge To Foreign Buys Of U.S. Firms  Investor's Business Daily3 days ago

Patents mean big business to big pharma

What it means to be 'big pharma' in a $980 billion industry (Part 4 of 10) ( Continued from Part 3 ) What are patents? A patent is an exclusive right granted for an invention. Patent protection means the invention cannot be commercially made, ...
 Yahoo! Finance3 days ago Hedge fund exec aims new legal weapon at Big Pharma's 'evergreened' patents  FiercePharma1 month ago

Paratek Pharmaceuticals, Inc. To Present At The Cowen and Company Healthcare Conference

BOSTON, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a clinical late stage biopharmaceutical company developing and commercializing novel tetracycline based antibiotics to treat serious infections where resistance ...
 BioSpace3 days ago Paratek Pharmaceuticals to Present at the Cowen Healthcare Conference  MoneyShow.com4 days ago Paratek to Receive $4 Million Payment From Actavis With Initiation of Phase 3 Trial of Sarecycline  Market Pulse Navigator1 month ago Paratek Pharmaceuticals, Inc. To Receive $4 Million Payment From Actavis With Initiation Of Phase 3 Trial Of Sarecycline  BioSpace1 month ago
[x]  

How to Invest in Breakthrough Biotech

You may know me best for my recommendations and predictions for gold, energy and other natural resources. You probably know that supply and demand drive commodity prices. But what's driving this supply and demand? In many cases, it's ...
 Uncommon Wisdom Daily4 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - warner chilcott
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less